NewsRoom Articles - Page 24 of 44

FridayApr 14, 2023 9:45 am

Lidar Pioneer Cepton, Inc. (NASDAQ: CPTN) Bridges Technological Gaps to Advance Mass Market ADAS Adoption

Cepton unveiled its Vista(R)-X120 Plus earlier this year at CES 2023, one of the largest tech tradeshows this year, where it was named a CES 2023 innovation award honoree for next-generation lidar products Vista(R)-X120 Plus features a wider field of view, software-definable regions of interest, and faster data transmission with a target price below $500, enabling high-volume production and faster mass-market adoption Vista(R)-X120 Plus is smaller and lighter, allowing for seamless integration without significantly affecting vehicle design Cepton collaborates with many global OEMS, and recently won the largest commercial lidar deployment contract in the tolling sector to date Advanced Driver…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

TuesdayApr 11, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim analysis expected in the third quarter of 2023 So far, CNS Pharmaceuticals has opened over 40 of 59 planned clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S. As an aside, the…

MondayApr 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active…

WednesdayApr 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)…

TuesdayApr 04, 2023 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Announces 2022 Financial Results With 65% YoY Growth in Revenues

Cepton, Inc. recently published its 4Q22 and FY22 financial results The company revealed that it had generated FY22 revenues of $7.4 million, up by 65% relative to FY21 results. Furthermore, Cepton guided for FY23 revenues of $15-20 million Cepton is at the forefront of lidar technology development, a position they’ve further consolidated with the recent launch of their award-winning Vista® X-120 Plus sensors Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance MMT® lidar solutions, recently announced their financial results for the fourth quarter and full year ending December 31, 2022 (https://ibn.fm/6wp95). The company reported full year 2022…

MondayApr 03, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever

Chris Bunka, Lexaria’s CEO, remains confident that 2023 will be Lexaria’s best year ever and has expressed his optimism that the company will continue to build its client base and increase its cash flows as the year progresses In his 2023 letter to stakeholders, the CEO expressed his satisfaction given that the company had delivered on a statement that he made the previous year, lauding his team for meeting objectives that Lexaria had set out to achieve in the 2022 calendar year Through the help of his team, Bunka is committed to making Lexaria one of the top drug delivery…

WednesdayMar 29, 2023 10:30 am

Market Analysis Endorsement Boosts Prospects of OTR Shipping Optimizer Freight Technologies Inc. (NASDAQ: FRGT)

The multi-billion dollar commerce in B2B international exports within the USMCA (formerly NAFTA) North American trading compact as well as likewise valuable domestic shipments represents a massive market Freight Technologies, also known as Fr8Tech, is innovating tech solutions for shipping efficiency within the USMCA territory The company’s flagship offering under its suite of technology-based solutions is branded Freight App, Inc. (or Fr8App) — a cloud-based freight matching platform that connects producers and carriers and helps them track shipments in real time Investment and research firm Chardan Capital Research recently issued a buy rating for Fr8Tech that highlights the company’s value…

MondayMar 27, 2023 11:15 am

CISO Global Inc. (NASDAQ: CISO) Committed to Building Client Trust, Attains ‘Highest Standard’ with SOC 2 Certification

CISO achieves SOC 2 Type II certification following annual audit President says company is committed to building relationships of trust with clients Achieving certification symbolizes commitment to safeguarding customers’ data As an industry leader in global cybersecurity and compliance services, CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., recently reached a significant milestone (https://ibn.fm/BNFYO). The company announced that it has achieved SOC 2(R) Type II certification following its annual SOC 2 Type II audit. “We believe that the relationship with our clients must be built on trust,” said Ashley Devoto, president and chief information security officer of Cerberus Sentinel.…

FridayMar 24, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs

DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000